Device Trial Radar · NCT07756411
Selective, Micropulse and Pattern Laser Trabeculoplasty in Medically Treated Open-angle Glaucoma.
Last checked: Nov 20, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
90
Actual
Start
Feb 1, 2025
Primary completion
Apr 1, 2026
Study completion May 1, 2026
Sponsor
- Lead sponsor
- University of UdineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 10, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized, single-centre, three-arm trial compared three subvisible laser trabeculoplasty delivery protocols in eyes with open-angle glaucoma already receiving intraocular pressure (IOP)-lowering medication: selective laser trabeculoplasty (SLT, 3-nanosecond pulses), micropulse laser trabeculoplasty (MLT, 577 nm with 15% duty cycle), and pattern laser trabeculoplasty (PLT, 5-ms pattern delivery). Ninety eyes of 90 patients were allocated 1:1:1 to a single 360-degree session and followed for 6 months. The primary outcome was IOP at 6 months, with an equivalence margin of +/-2.0 mmHg prespecified for pairwise comparisons. Secondary outcomes were percentage IOP change, number of IOP-lowering medications, cumulative treatment success (IOP reduction of at least 20% from baseline without an increase in medications), and adverse events. Outcome assessment was performed by a second ophthalmologist masked to allocation and to clinical history.
Conditions
- Open-Angle Glaucoma
- Ocular Hypertension
Interventions
Selective laser trabeculoplastyDevice
Nanosecond-pulse laser trabeculoplasty delivered over 360 degrees with a Tango laser (Ellex Medical Lasers, Adelaide, Australia) after two drops of pilocarpine 2% and topical anaesthetic.
Micropulse laser trabeculoplastyDevice
Micropulsed 577-nm laser trabeculoplasty delivered over 360 degrees with an IQ 577 laser (Iridex, Mountain View, California, USA) after two drops of pilocarpine 2% and topical anaesthetic.
Pattern laser trabeculoplastyDevice
Short-exposure pattern laser trabeculoplasty delivered over 360 degrees with a Pascal Streamline 577 (Topcon, Tokyo, Japan) after two drops of pilocarpine 2% and topical anaesthetic.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Intraocular pressure at 6 monthsTime frame: 6 months after treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Glaucoma Unit, Department of Medicine - Ophthalmology, University of Udine
Udine, UD, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.